AKT1 and cancer: Growing evidence has suggested that the dual blocking of the RAF/MEK/ERK and PI3K/PDK1/Akt signal axes is an effective means to exploit novel drug candidates for cancers (Ciuffreda et al., 2014; Temraz, Mukherji & Shamseddine, 2015).